1. Introduction {#sec1}
===============

Critical limb ischemia (CLI) is the most dangerous stage of peripheral artery disease (PAD) caused by distal tissue hypoxia injury and lack of blood supply, including distal extremity ischemia, ulcers, or gangrene \[[@B1], [@B2]\]. The prevalence of PAD in the general population is 3% to 10% \[[@B3], [@B4]\]. The data showed that 11.2% of patients with PAD would deteriorate to CLI each year, and the patient with CLI had the high amputation and mortality rates \[[@B5]\]. Currently, patients in PAD could be treated by percutaneous transluminal angioplasty (PTA) or intravascular thrombolysis \[[@B6], [@B7]\]; however, 10%--30% of patients with CLI are not candidates for revascularization surgery. Many patients lose the chance of PTA, and the prognosis is poor after surgery, because the patients have peripheral atherosclerosis obliterans, extensive vascular disease, and/or serious damage caused by severe ischemic lesions of limbs \[[@B8], [@B9]\]. The studies \[[@B3], [@B10]\] found that vascular remodeling and other means still cannot alleviate the symptoms of ischemia. The amputation rate is 10%--40%, and the mortality rate is up to 20% in patients with CLI within 6 months \[[@B11]\]. The angiogenesis is the optimal treatment for CLI, and autologous stem cell therapy is an emerging alternative treatment \[[@B12], [@B13]\].

Since 2002, Tateishi-Yuyama et al. \[[@B14]\] have reported that bone marrow mononuclear cell transplantation was safe and effective for therapeutic angiogenesis in patients with CLI and it could significantly promote ulcer healing and reduce the amputation rate. During the past decades, a large number of basic researches and clinical treatment had been focused on stem cell transplantation for CLI \[[@B15]\]. The stem cell transplantation may improve pathophysiologic processes by stimulating the activities of tissue repair cells and inducing into vascular endothelial cells \[[@B16], [@B17]\]. However, only few evidences were available regarding safety and efficacy of autologous stem cell therapy in CLI. Meta-analyses have already become supporting evidence-based medicine. Although, there were some meta-analyses of stem cell therapy in CLI, the small amount of studies or incomplete indicators lead to the results of deviation and unconvinced \[[@B18], [@B19]\]. Therefore, this study of 23 RCTs with a total of 962 patients was included in order to acquire high-quality evidence for the clinical efficacy and safety of autologous stem cell therapy in CLI.

2. Methods {#sec2}
==========

2.1. Literature Search {#sec2.1}
----------------------

We searched the clinical studies, including SinoMed, PubMed, Embase, [http://ClinicalTrials.gov](http://clinicaltrials.gov/), and Cochrane Controlled Trials Register databases from building database to January 2018. Using the terms number 1 "stem cells," "mononuclear cells," "granulocyte colony-stimulating factor," "G-CSF," "peripheral blood," and "bone marrow," the above search terms were connected with "OR". Number 2 "critical limb ischemia," "peripheral arterial disease," "peripheral vascular disease," "diabetic foot," "revascularization," "angiogenesis," or "arteriogenesis", the above search terms were connected with "OR". Number 3 "randomized controlled". Then, the above search terms of number 1, number 2, and number 3 were connected with "AND". We manually searched the references of the original and review articles for possible related studies.

2.2. Study Selection {#sec2.2}
--------------------

For the systematic review, we searched 23 clinical studies that met the following criteria: (1) patients with PAD or CLI, (2) received autologous stem cell therapy, (3) reported as randomized controlled trials (RCTs), (4) the control group received standard therapy with or without sham injections, (5) at least 1-month follow-up, and (6) reported efficacy and safety issues.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Two of the authors independently extracted the data of literature and made a quality assessment process according to the predefined inclusion criteria. Difference among the two authors was solved by discussion with the third author. We used the Cochrane risk of bias tool for the quality evaluation of the included studies. This quality evaluating strategy included criteria concerning aspects of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other biases \[[@B20]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

In this meta-analysis, statistical analysis was performed using RevMan software version 5.3 and we used risk ratio (RR) with 95% confidence interval (CI) for the analysis of dichotomous data, whereas the continuous data were presented as weighted mean difference (MD) or standardized mean difference (SWD) with 95% CI. Heterogeneity between the studies was determined using the chi-square test, with the *I*^2^ statistic, where *I*^2^ \< 25% represent mild inconsistency, values between 25% and 50% represent moderate inconsistency and values \> 50% suggest severe heterogeneity between the studies. We defined *I*^2^ \> 50% as an indicator of significant heterogeneity among the trials. We used random effects\' models to estimate the pooled results to minimize the influence of potential clinical heterogeneity among the studies, and the statistical significance was assumed at *P* \< 0.05. Subgroup analysis was assessed using the *χ*^2^ test. Sensitivity analysis was performed to evaluate the robustness of merged results, by removing individual study. Publication bias was assessed by means of funnel plots.

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

A systematic search of studies published until January 2018 was performed through SinoMed, PubMed, Embase, [http://ClinicalTrials.gov](http://clinicaltrials.gov/), and Cochrane Controlled Trials Register databases from building database. A total of 1130 literatures were searched, 23 RCTs were included in the inclusion criteria, and the literature search procedure was shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Study Characteristics {#sec3.2}
--------------------------

The general characteristics of the included studies were listed in [Table 1](#tab1){ref-type="table"}. The included studies were 23 RCTs with a total of 962 patients. In these studies, the cell therapy group was one of the following stem cells: bone marrow mononuclear cells (BMMNCs, *n* = 7 studies), bone marrow mesenchymal stem cells (BMMSCs, *n* = 4 studies), bone marrow stem cells (BMSCs, *n* = 5 studies), peripheral blood mononuclear cells (PBMNCs, *n* = 2 studies), peripheral blood stem cells (PBSCs, *n* = 4 studies), CD34+ (*n* = 1 study), or CD133+ stem cells (*n* = 1 study). The transplantation method of stem cell was intramuscular (*n* = 20 studies) or intra-arterial (*n* = 3 studies). The patients in the control group received either placebo or standard care (*n* = 23 studies). The dose of stem cells was divided into three groups: high dose (10^9^, *n* = 5 studies), medium dose (10^8^, *n* = 5 studies), and low dose (10^7^, *n* = 5 studies). The mean follow-ups of the studies were 3 months (*n* = 9 studies), 6 months (*n* = 8 studies), and 12 months (*n* = 3 studies).

3.3. Quality Assessment {#sec3.3}
-----------------------

The risks of biases of the included studies were evaluated by the Cochrane assessment tool, and these results were summarized in [Table 2](#tab2){ref-type="table"}. Three of the studies were at high risk of bias for blinding of participants and personnel and other biases according to the Cochrane Collaboration tool. Five studies reported methods of random sequence, and three studies reported the details of allocation concealment.

3.4. Amputation Rate {#sec3.4}
--------------------

Amputation rate was reported in 18 studies with a total of 512 patients treated with cell therapy and 525 patients in the control groups ([Figure 2](#fig2){ref-type="fig"}). Cell therapy was associated with a significant 41% reduction in the amputation rate, compared with control groups (RR = 0.59, 95% CI = 0.46--0.76, *P* \< 0.0001). Subgroup analyses indicated that peripheral blood stem cell (PBSC) was more beneficial than bone marrow stem cell (BMSC) on the amputation rate (*P* = 0.03, *I*^2^ = 78.6%). Intramuscular of autologous stem cell transplantation was better than intra-arterial in reducing the amputation rate (*P* = 0.05, *I*^2^ = 75%). The mean follow-ups of the studies were divided into 3 months, 6 months, and 12 months, and the group of 3 months was a significant difference compared with 6 months and 12 months (*P* = 0.03). Subgroup analysis among high dose (10^9^), medium dose (10^8^), and low dose (10^7^) showed that the group of low dose (10^7^) had a significant effect in reducing the amputation rate.

3.5. Ulcer Healing and Pain-Free Walking Distance {#sec3.5}
-------------------------------------------------

Ulcer healing was included in the analysis of 18 studies ([Figure 3](#fig3){ref-type="fig"}). Results of analysis showed that cell therapy could significantly increase the probability of ulcer healing (RR = 1.73, 95% CI = 1.45--2.06, *P* \< 0.00001). Subgroup analyses indicated that the low dose (10^7^) group of autologous stem cell transplantation was better than the other groups in ulcer healing (RR = 3.55, 95% CI = 1.95--6.48, *P* = 0.02). Pain-free walking distance significantly increased in cell therapy (MD = 144.84, 95% CI = 53.03--236.66, *P* = 0.002) ([Figure 4](#fig4){ref-type="fig"}).

3.6. Ankle-Brachial Index (ABI) and Transcutaneous Oxygen Tension (TcO~2~) {#sec3.6}
--------------------------------------------------------------------------

ABI with 15 studies was included in the analysis ([Figure 5](#fig5){ref-type="fig"}). Results indicated that cell therapy significantly improved the ABI by 0.13 (MD = 0.13, 95% CI = 0.11--0.15, *P* \< 0.00001). Subgroup analyses indicated that bone marrow mesenchymal stem cells (BMMSCs) were superior to bone marrow mononuclear cells (BMMNCs), but there was no significant difference between bone marrow stem cells (BMSCs) and peripheral blood stem cells (PBSCs) in improving the ABI. The TcO~2~ with 8 studies was included in the analysis. Results indicated that cell therapy significantly improved TcO~2~ by 12.22 mmHg (MD = 12.22, 95% CI = 5.03--19.41, *P* = 0.0009). Subgroup analyses showed that there was no beneficial effect between BMSCs and PBSCs on the TcO~2~ ([Figure 6](#fig6){ref-type="fig"}).

3.7. Angiogenesis and Blood Flow of 10 Toes {#sec3.7}
-------------------------------------------

There were 8 studies included in the analysis with angiogenesis ([Figure 7](#fig7){ref-type="fig"}). Analysis by digital subtraction angiography revealed that autologous stem cell transplantation significantly improved the new vessel form (RR = 5.91, 95% CI = 2.49--14.02, *P* \< 0.0001). The number of ischemic limbs with rich new collateral vessels in the transplant patients was significantly higher than that in the control group. Meanwhile, the blood flow of 10 toes significantly increased in cell therapy (SMD = 0.83, 95% CI = 0.48--1.18, *P* \< 0.00001) ([Figure 8](#fig8){ref-type="fig"}).

3.8. Publication Bias and Heterogeneity {#sec3.8}
---------------------------------------

According to this meta-analysis, the significant symmetry showed that the ABI did not have obvious publication bias. Furthermore, the Egger\'s test funnel plot also indicated that there was no obvious publication bias in the ABI (*P* \> 0.363, 95% CI = −0.57--1.45) ([Figure 9](#fig9){ref-type="fig"}). Sensitivity analysis was performed using a Galbraith plot for all the indicators. The results showed that there was no substantial change in the ABI and amputation rate, indicating that the results of meta-analysis were credible ([Figure 10](#fig10){ref-type="fig"}).

4. Discussion {#sec4}
=============

4.1. Main Outcome {#sec4.1}
-----------------

The registrations of stem cell clinical trials were retrieved on USA National Institutes of Health (NIH) clinical trial registration website ([http://ClinicalTrials.gov](http://clinicaltrials.gov/)). We performed the databases from building database to January 2018. There were 4715 clinical trial registration information for stem cells all over the world, and there were 2399 studies in America, 1027 studies in Europe, and 574 studies in China. We analyzed the disease of stem cell therapy and found that there were 1767 studies on neoplasms by histologic type, 1279 studies on immune system diseases, 607 studies on vascular diseases, and 513 studies on bone marrow diseases. The data showed that stem cell therapy has been used in various diseases, and stem cell therapy is approved in the globe. This meta-analysis included 23 RCTs with a total of 962 patients with CLI who were ineligible for surgical or percutaneous revascularization. Results indicated that autologous stem cell therapy had the potential effect to reduce the risk of amputation by 41% and significantly increased the probability effect of ulcer healing by 73% compared with the control group. ABI and TcO~2~ are the basic indicators of CLI, and the results indicated that cell therapy significantly improved the ABI by 0.13 and TcO~2~ by 12.22 mmHg. Moreover, the value of the increased ABI and TcO~2~ level were meaningful to confirm the truth of the improvements of amputation and wound healing rates. In addition, cell therapy could improve the endpoints of limb perfusion, and the blood flow of 10 toes significantly increased in cell therapy, compared with the control group. We speculated that the main reason for the increases of limb perfusion was angiogenesis. The studies reported that endothelial progenitor cells (EPCs) derived from the bone marrow can facilitate microvasculature regeneration by paracrine or direct mechanisms in regions of blood vessel formation \[[@B21], [@B22]\]. Therefore, we made a statistics on the use of angiography in patients with CLI. There were 8 studies with RCTs in the analysis, revealing a significant effect of angiogenesis after autologous stem cell transplantation.

4.2. Subgroup Analysis {#sec4.2}
----------------------

A study by Tateishi-Yuyama et al. \[[@B14]\] reported that transplantation of bone marrow stem cell therapy in patients with CLI significantly improved TcO~2~, ABI, and pain-free walking distance. Hereafter, many studies with RCTs had investigated the safety and feasibility of autologous stem cells of BMMNC therapy in CLI \[[@B5], [@B15], [@B23]--[@B26]\]. In recent years, a variety of cell types have been studied for treatment of PAD or CLI, including PBSCs, BMSCs, BMMNCs, PBMNCs, and BMMSCs. Our subgroup analyses indicated that PBSCs were more beneficial than BMSCs on the amputation rates. Dubsky et al. \[[@B13], [@B27]\] suggested that there was no significant difference in long-term prognosis between patients treated with BMMNCs and those treated with PBMNCs. The trials reported that transplantation of BMMSCs was safe and no serious adverse events by cell injection after the follow-up period \[[@B28], [@B29]\]. RCTs by Lu et al. \[[@B15]\] suggested that ulcer healing, ABI, TcO~2~, painless walking time, and magnetic resonance angiography (MRA) in the BMMSC group were significantly higher than that in the BMMNC group in diabetic patients with CLI. The subgroup analyses indicated that BMMSCs showed beneficial effect than BMMNCs in improving the ABI. Therefore, BMMSCs could be more effective than BMMNCs in the treatment of CLI.

In RCTs of patients with CLI, the most common route of stem cell therapy administration was intramuscular. But, the potential route of intra-arterial was also injected therapy \[[@B5], [@B25], [@B30]\]. In order to find suitable and beneficial injection therapy, we conducted subgroup analysis. The results showed that the amputation rate in the intramuscular group was significantly lower than that in the intra-arterial group. The JUVENTAS trial is the largest RCT to investigate the effects of BMMNCs by intra-arterial \[[@B5]\]. The study \[[@B5]\] reported that repetitive intra-arterial of autologous BMMNCs was not effective in reducing the primary outcome of the amputation rate at 6 months, ABI, ulcer healing, and TcO~2~. Therefore, we suggest that stem cell administration is suitable and beneficial choice by intramuscular injection. In addition, we found that the low dose (10^7^) group was a significant difference on the amputation rate compared with high dose (10^9^) and medium dose (10^8^) groups (*P* = 0.03), and cell therapy with low dose (10^7^) significantly reduced the amputation rate. The cell therapy with low dose (10^7^) showed a significant improvement in ulcer healing in patients with CLI \[[@B26], [@B31], [@B32]\]. However, a degree of heterogeneity may be generated in subgroup analysis, which could negatively impinge upon the assessment on efficacy of cell therapy. The generated heterogeneity could mask the true effect of cell therapy \[[@B10]\]. So we think that the results of subgroup analysis need the large clinical trials as evidence to support.

4.3. Safety {#sec4.3}
-----------

The studies of 23 RCTs showed that cell therapy was relatively safe, and the adverse events were mostly mild and transient. Teraa et al. \[[@B5]\] reported that there was a patient with inguinal hematoma due to intra-arterial injection, and the study of Szabo et al. \[[@B33]\] found that the cell therapy group had three adverse events during 3 months, but there was no evidence that the adverse events were attributed to stem cell transplantation. Li et al. \[[@B26]\] reported that there are three patients with fever in the cell therapy group, and they were cured after treatment. Lu et al. \[[@B15]\] showed that a few patients had a short-term response of mild pain 2 hours after cell transplantation, but no complications were detected, such as immune rejection and allergic reactions. Wen and Huang \[[@B34]\] reported that some patients felt uncomfortable of their limbs after intramuscular injection of PBSCs within 1 week, and the intramuscular injection site did not appear infected during 3-month follow-up. Similarly, many studies reported that stem cell transplantation was safe in long-term follow-up \[[@B28], [@B35]\]. The study by Molavi et al. \[[@B36]\] showed no adverse events during the 24-week follow-up period after cell delivery. No serious adverse events were found in the 23 studies included in this meta-analysis. Therefore, autologous stem cell transplantation is safe in the treatment of CLI.

In conclusion, this meta-analysis suggests that autologous stem cell therapy is safe and effective in CLI. Subgroup analysis indicates that cell types, cell dosage, route of administration, and follow-up time are the very important factors in stem cell therapy. However, we still lack high quality and large scale of RCTs to explore the influence of factors and the effect of autologous stem cell therapy in CLI.
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![Flow chart and strategy of the meta-analysis.](SCI2018-7528464.001){#fig1}

![Forest plot of meta-analysis of the amputation rate in cell therapy and standard care for critical limb ischemia. (a) Subgroup analyses of bone marrow stem cells (BMSCs) versus peripheral blood stem cells (PBSCs). (b) Subgroup analyses of intramuscular (IM) versus intra-arterial (IA). Squares indicate the risk ratio, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.002){#fig2}

![Forest plot of meta-analysis of ulcer healing in cell therapy and standard care for critical limb ischemia. (a) Subgroup analyses of bone marrow stem cells (BMSCs) versus peripheral blood stem cells (PBSCs). (b) Subgroup analyses among high dose (10^9^), medium dose (10^8^), and low dose (10^7^). Squares indicate the risk ratio, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.003){#fig3}

![Forest plot of meta-analysis of pain-free walking distance in cell therapy and standard care for critical limb ischemia. Squares indicate the weighted mean difference, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.004){#fig4}

![Forest plot of meta-analysis with the ankle-brachial index (ABI) in cell therapy and standard care for critical limb ischemia. (a) Subgroup analyses of bone marrow stem cells (BMSCs) versus peripheral blood stem cells (PBSCs). (b) Subgroup analyses among bone marrow mononuclear cells (BMMNCs) and bone marrow mesenchymal stem cells (BMMSCs). Squares indicate the weighted mean difference, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.005){#fig5}

![Forest plot of meta-analysis with transcutaneous oxygen tension (TcO~2~) in cell therapy and standard care for critical limb ischemia. Subgroup analyses of bone marrow stem cells (BMSCs) versus peripheral blood stem cells (PBSCs). Squares indicate the weighted mean difference, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.006){#fig6}

![Forest plot of meta-analysis with angiogenesis in cell therapy and standard care for critical limb ischemia. Squares indicate the risk ratio, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.007){#fig7}

![Forest plot of meta-analysis with blood flow of 10 toes in cell therapy and standard care for critical limb ischemia. Squares indicate the standardized mean difference, and horizontal lines represent 95% confidence intervals.](SCI2018-7528464.008){#fig8}

![Meta-analysis of publication bias of the ankle-brachial index (ABI) in cell therapy and standard care for critical limb ischemia. (a) Funnel plot of the ABI. (b) Egger\'s funnel plot of the ABI.](SCI2018-7528464.009){#fig9}

![Meta-analysis of sensitivity in cell therapy and standard care for critical limb ischemia. (a) Galbraith plot of the ankle-brachial index (ABI). (b) Galbraith plot of the amputation rate.](SCI2018-7528464.010){#fig10}

###### 

Characteristics of included clinical studies.

  Study                             Sample (T/C)   Age (T/C)   Intervention   Injection        Follow-up   Number of cells   Evaluation                   
  --------------------------------- -------------- ----------- -------------- ---------------- ----------- ----------------- ---------------------------- ------------------
  Huang et al. \[[@B37]\]           14/14          71.1/70.9   PBMNCs         Standard care    IM          12 w              3 × 10^9^                    ①, ②, ③, ④, ⑥, ⑦
  Arai et al. \[[@B23]\]            13/12          62/68       BMMNCs         Standard care    IM          1 mo              1--3 × 10^9^                 ②, ⑤
  Barć et al. \[[@B24]\]            14/15          Unclear     BMMNCs         Standard care    IM          6 mo              Unclear                      ①, ②
  Lu et al. \[[@B38]\]              22/23          66.6/65.5   BMMSCs         Standard care    IM          12 w              7.32 × 10^8^--5.61 × 10^9^   ①, ②, ③, ④, ⑥
  Dash et al. \[[@B39]\]            12/12          40          BMMSCs         Standard care    IM          12 w              4.5-6 × 10^7^                ②, ⑥
  Shi et al. \[[@B40]\]             25/25          Unclear     BMSCs          Standard care    IM          3 mo              Unclear                      ②, ④, ⑦
  Procházka et al. \[[@B30]\]       42/54          66.2/64.1   BMSCs          Standard care    IA          4 mo              1.96 × 10^8^                 ①, ②, ③
  Wen and Huang \[[@B34]\]          30/30          63          PBSCs          Standard care    IM          3 mo              3 × 10^9^                    ①, ②, ③, ④, ⑦
  Lu \[[@B15]\]                     21/41          63          BMMNCs         Standard care    IM          24 w              9.3 × 10^8^                  ①, ②, ③, ④, ⑤
  Lu et al. \[[@B15]\]              20/41          65          BMMSCs         Standard care    IM          24 w              9.6 × 10^8^                  ①, ②, ③, ④, ⑤
  Walter et al. \[[@B25]\]          19/21          64.4/64.5   BMMNCs         Standard care    IA          6 mo              1.53 × 10^8^                 ①, ④, ⑤
  Jain et al. \[[@B41]\]            25/23          54/58       BMSCs          Standard care    IM          3 mo              Unclear                      ②
  Benoit et al. \[[@B42]\]          34/14          65.7/72.5   BMSCs          Standard care    IM          6 mo              Unclear                      ①, ②
  Losordo et al. \[[@B43]\]         16/12          66.2/67.1   CD34+          Standard care    IM          12 mo             1 × 10^6^ 1 × 10^5^          ①, ④
  Powell et al. \[[@B44]\]          48/24          67.3/69.2   BMSCs          Standard care    IM          12 mo             0.35--2.95 × 10^8^           ①
  Ozturk et al. \[[@B31]\]          20/20          71.9/70.8   PBMNCs         Standard care    IM          3 mo              2.48 × 10^7^                 ①, ②, ③, ④, ⑤, ⑥
  Gupta et al. \[[@B29]\]           10/10          43/47.6     BMMSCs         Standard care    IM          6 mo              2 × 10^9^                    ①, ②, ④
  Li et al. \[[@B26]\]              29/29          61/63       BMMNCs         Standard care    IM          6 mo              1 × 10^7^                    ①, ②
  Mohammadzadeh et al. \[[@B32]\]   7/14           63.5/64.2   PBSCs          Standard care    IM          3 mo              2 × 10^7^                    ①, ②, ④
  Szabo et al. \[[@B33]\]           10/10          60.6/63     PBSCs          Standard care    IM          24 mo             6.64 × 10^7^                 ②, ⑤
  Raval et al. \[[@B9]\]            7/3            65/85       CD133+         Standard care    IM          12 mo             5--40 × 10^7^                ①
  Teraa et al. \[[@B5]\]            81/79          69/65       BMMNCs         Standard care    IA          6 mo              5-6 × 10^8^                  ①, ②, ④, ⑤
  Skóra et al. \[[@B45]\]           16/16          66.7/68.3   BMMNCs         Pentoxifylline   IM          3 mo              1.58 × 10^9^                 ①, ③, ④
  Lu et al. \[[@B46]\]              20/21          67.2        PBSCs          Standard care    IM          6 mo              Unclear                      ④, ⑤

Note: T = cell therapy; C = control group; IM = intramuscular; IA = intra-arterial; w = week; mo = month; PBMNCs = peripheral blood mononuclear cells; BMMNCs = bone marrow mononuclear cells; BMMSCs = bone marrow mesenchymal stem cells; BMSCs = bone marrow stem cells; PBSCs = peripheral blood stem cells; ① = amputation; ② = ulcer healing; ③ = angiographic; ④ = ABI; ⑤ = TcO~2~; ⑥ = pain-free walking distance; ⑦ = the blood flow of 10 toes.

###### 

Cochrane risk of bias assessment.

  Study                             Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other biases
  --------------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- --------------
  Huang et al. \[[@B37]\]           Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Unclear               Low
  Arai et al. \[[@B23]\]            Unclear                      Unclear                  High                                     Unclear                          Low                       Low                   Low
  Barć et al. \[[@B24]\]            Unclear                      Unclear                  High                                     Unclear                          Low                       Low                   Low
  Lu et al. \[[@B38]\]              Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Low                   Low
  Dash et al. \[[@B39]\]            Unclear                      Unclear                  High                                     Unclear                          Low                       Unclear               Low
  Shi et al. \[[@B40]\]             Unclear                      Unclear                  High                                     Unclear                          Low                       Low                   High
  Procházka et al. \[[@B30]\]       Low                          Low                      High                                     Unclear                          Low                       Low                   Low
  Wen and Huang \[[@B34]\]          Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Low                   High
  Lu \[[@B15]\]                     Unclear                      Unclear                  Low                                      Unclear                          Low                       Unclear               Low
  Lu et al. \[[@B15]\]              Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Walter et al. \[[@B25]\]          Unclear                      Unclear                  Low                                      Unclear                          Low                       Unclear               Low
  Jain et al. \[[@B41]\]            Low                          Low                      Low                                      Unclear                          Low                       Unclear               Low
  Benoit et al. \[[@B42]\]          Unclear                      Unclear                  Low                                      Unclear                          Low                       Low                   Low
  Losordo et al. \[[@B43]\]         Unclear                      Unclear                  Low                                      Low                              Low                       Unclear               Low
  Powell et al. \[[@B44]\]          Unclear                      Unclear                  Low                                      Unclear                          Low                       Unclear               Low
  Ozturk et al. \[[@B31]\]          Unclear                      Unclear                  High                                     Unclear                          Low                       Low                   Low
  Gupta et al. \[[@B29]\]           Low                          Low                      Low                                      Low                              Low                       Low                   Low
  Li et al. \[[@B26]\]              Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Unclear               Low
  Mohammadzadeh et al. \[[@B32]\]   Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Low                   Low
  Szabo et al. \[[@B33]\]           Unclear                      Unclear                  High                                     Low                              Low                       Low                   Low
  Raval et al. \[[@B9]\]            Unclear                      Unclear                  Low                                      Low                              Low                       Low                   Low
  Teraa et al. \[[@B5]\]            Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Skóra et al. \[[@B45]\]           Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Lu et al. \[[@B46]\]              Unclear                      Unclear                  High                                     Low                              Low                       Low                   High

Note: low = low risk of bias; unclear = unclear risk of bias; high = high risk of bias.
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